

1 Trends in fluoroquinolone prescribing
2 in UK primary and secondary care
3 between 2019 and 2023.

4

5

6

7

8 Fergus Hamilton^{1,2}, Elizabeth Darley², Alasdair MacGowan²

9

10

11 1. MRC Integrative Epidemiology Unit, University of Bristol

12 2. Infection Science, North Bristol NHS Trust

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

Introduction

Fluoroquinolones are important, widely used antibiotics but have associations with a significant number of adverse outcomes. A recent (January 2024) decision by the UK drug regulator, the Medicines and Health Regulatory Authority (MHRA), restricted systemic use of these antibiotics to when only absolutely necessary with immediate effect. One stated reason for the ban was the failure of previous guidance (2019, 2023), to impact prescribing, with the 2023 MHRA Drug Safety Update stating there had been “no change in prescribing” of fluoroquinolones in relation to guidance.

Methods

We evaluated the trend in prescribing of fluoroquinolones and comparator antibiotics using national data for all primary care practices in England from 2019 to 2023. We calculated the percent change in prescribing of fluoroquinolones using linear regression, comparing with other antibacterials. Analyses were then performed at the integrated care board (ICB) level. We also performed a similar analysis on secondary care prescribing and included hospital inpatient stay data.

Results

In primary care, there was a clear negative trend in fluoroquinolone (particularly ciprofloxacin) item dispensing, with a 4.2% reduction in items dispensed per year, 95% confidence interval, CI (-5.2% ; -3.3%, $p = 6 \times 10^{-13}$). This occurred despite no change in overall antibacterial prescription (+2% -0.56% ; +4.6%, $p = 0.12$) and no decrease in comparator antibiotics. These occurred across nearly all (97/101) ICBs. Secondary care data showed stable prescription of fluoroquinolones, but other comparator antibiotics increased, leading to relatively fewer prescriptions compared to other agents.

Conclusions

There was a marked reduction in fluoroquinolone prescribing in primary care in England in both absolute terms and relative to other antibiotics between 2019 to 2023. Relative reductions have occurred in secondary care.

Funding

Wellcome Trust (222894/Z/21/Z)

52 Introduction

53

54 Fluoroquinolones are a widely used class of antibiotics.¹ They are effective therapy for Gram-
55 negative, Gram-positive, and (for some agents) anaerobic bacteria.¹ The most commonly used
56 agents are ciprofloxacin, levofloxacin, and moxifloxacin, although the first two are far more
57 common. Given their broad spectrum of in-vitro activity and generally favourable
58 pharmacokinetics, they are widely recommended across a broad range of infection indications,
59 particularly in patients with penicillin allergy. They were (until very recent MHRA
60 announcements²) the recommended option for severe community acquired pneumonia (CAP)
61 with a penicillin allergy in UK National Institute for Clinical Excellence (NICE) guidance³. They
62 are also recommended in the 2019 Infectious Diseases Society of America/American Thoracic
63 Society (IDSA/ATS) pneumonia guidance,⁴ and as first line and/or recommended in penicillin
64 allergy or under other conditions in conditions as broad as prosthetic joint infection, legionella
65 pneumonia⁴, sexually transmitted infections⁵, typhoid fever⁶, pyelonephritis⁷, tuberculosis⁸ and
66 Gram-negative infections including bacteraemia⁹. For some deep tissue infections they may be
67 given for a course lasting several weeks or months, and are the preferred therapy. Given the
68 paucity of effective oral agents for Gram negative infection and high resistance rates to other
69 drugs, fluoroquinolones are highly valuable agents. For infections caused by some organisms
70 such as *Pseudomonas aeruginosa*, they are the only oral option.

71

72 Despite these benefits, fluoroquinolones are known to associate with a range of adverse
73 events.¹⁰ Well established and proven causal associations include tendonitis and *C. difficile*
74 infection, but over the past 20 years, an increasing number of associations have been identified
75 including QTc prolongation, aortic dissection, aortic aneurysm and (sometimes severe)
76 psychiatric associations.¹⁰ Regulators have been aware of these risks for some time, with the
77 first FDA ‘black box’ warning in 2008 (related to tendonitis).¹¹ More recently the European
78 Medicines Agency (EMA) and MHRA have produced multiple updates with increasing concern.
79 The EMA produced guidance suggesting use should be limited to only severe infection in March
80 2019 (due to the risk of tendonitis and potentially aortic dissection).¹² The MHRA have also
81 produced a number of updates, starting in 2019¹³, repeated in 2023¹⁴, and most recently, in
82 2024², a much tighter restriction of fluoroquinolone prescribing. This directs against any use of
83 systemic fluoroquinolone therapy except where absolutely necessary (e.g. no other drug can be
84 used). The extent of this ban resulted from an ongoing review of the evidence, increasing
85 patient reports via the national scheme (Yellow Card), and “no evidence of a change in
86 fluoroquinolone prescribing patterns” in relation to previous warnings¹⁴.

87

88 The reference for this “lack of change” in prescribing was a European pharmacovigilance
89 study¹⁵, which included 15 million UK participants from 2016 to 2020 and was commissioned by
90 the EMA to assess the impact of the 2019 EMA guidance across numerous countries. It was not
91 able to identify a reduction in fluoroquinolone usage directly in relation to the EMA guidance.¹⁵
92 However, this study did show that a) the UK had the lowest rates of fluoroquinolone prescribing
93 in all included countries, and b) the UK had around a 3% reduction per year in fluoroquinolone
94 prescriptions from 2016 to 2020 guidance.¹⁵

95

96 Given this study ended during 2020 (when impact of the COVID-19 strongly impacted
97 antimicrobial prescribing) and showed an apparent reduction in prescribing we performed a
98 study of UK fluoroquinolone prescribing in primary care using all of England primary care and
99 secondary care data. Our primary aim was to identify the recent trend in fluoroquinolone
100 prescribing.

101
102

103 **Methods:**

104

105 To evaluate trends in prescribing of fluoroquinolones, we extracted data on England wide
106 prescribing in both primary and secondary care datasets.

107

108

109 *Primary care dataset*

110

111 Primary care data was accessed via OpenPrescribing¹⁶, which extracts directly from NHS
112 primary care records for England. We extracted specific data on quinolones (as a class),
113 ciprofloxacin, and levofloxacin. Fluoroquinolones are the only regularly prescribed quinolones
114 in the U.K and so we use the terms interchangeably in this report. Ciprofloxacin accounted for
115 >95% of prescriptions, and no other quinolone agents were prescribed widely.

116

117 For comparison, we also extracted data on two comparator agents with similar spectrums of
118 activity: co-amoxiclav and co-trimoxazole. We also extracted total antibiotic use for all
119 penicillins, all antibacterials, and total medication use. Data was available from December
120 2018 until November 2023 (4 years 11 months), at a monthly level, and at Integrated Care Board
121 level. There are 101 Integrated Care Boards in ?England. Data is in the format of number of
122 prescriptions and quantity dispensed (as most prescriptions are for more than one dose). We
123 estimated defined daily doses (DDDs) using BNF dosing (i.e. as ciprofloxacin is dosed twice
124 daily), the quantity divided by two is the DDD.

125

126 *Secondary care dataset*

127

128 Secondary care data was accessed via (<https://hospitalmedicines.genomium.org/>)¹⁷ which in
129 turn extracts data from the NHSBSA SCMD dataset for England.¹⁸ We extracted data on
130 ciprofloxacin and levofloxacin, as well as comparator agents with similar spectrum of activity:
131 co-amoxiclav, piperacillin-tazobactam, co-trimoxazole, meropenem, clarithromycin,
132 amoxicillin, and ceftriaxone. As this dataset reports chemical products, we defined piperacillin-
133 tazobactam by tazobactam sodium, co-trimoxazole by sulfamethoxazole, and amoxicillin-
134 clavulanate by potassium clavulanate. None of these are widely used outside the antibiotic
135 combination. Data was available from April 2019 until November 2023, at a monthly level.

136

137 We estimated the number of prescriptions by assuming a 5-day course length for all infections
138 and assuming BNF standard dosing regimens. This led to one prescription being 5g for
139 Ciprofloxacin, 5g for levofloxacin, 15g for Meropenem, 15g for Amoxicillin, 5g for clarithromycin,
140 5g for Ceftriaxone 8g for co-trimoxazole (assuming 800mg per dose of sulfamethoxazole), 3g for

141 co-amoxiclav (assuming 200mg per dose of clavulanate, and IV therapy), and 7.5g for
142 piperacillin-tazobactam (assuming 500mg per dose of tazobactam). We recognise these are
143 assumptions and are simply produced to aid comparison with primary care prescribing.

144

145 *Hospital data*

146

147 From December 2020 until December 2023, NHS England produced monthly hospital utilisation
148 data. This is in the format of number of occupied bed days per month and forms part of the
149 Urgent and Emergency Care Situation Report.¹⁹

150

151 *Analytic approach*

152

153 As there have been numerous warnings from multiple drug regulators including the FDA, MHRA,
154 and EMA over this time , and as the interventions are likely not applied instantaneously, we took
155 the approach of visualising and quantifying change over time, rather than performing an
156 analysis at a specific time point. This approach has also been shown to be highly sensitive to
157 statistical methods and/or time points chosen.²⁰ Our datasets largely overlap although the first
158 major MHRA warnings and restriction occurred in March 2019, prior to our secondary care
159 dataset.

160

161 For this reason, and because of the increased potential for potentially less appropriate
162 prescribing occurs in primary care (due to the reduced severity of illness and reduced burden of
163 bacterial infection, and less use of fluoroquinolones in guidelines), we focus most of our
164 analysis on the primary care data but include the secondary care data for completeness.

165

166 We performed linear regression for each drug/drug class with date as the exploratory variable,
167 with the scale set to evaluate changes in prescriptions per year. Absolute prescription rates
168 were calculated with respect to the total English population in the given year. To aid
169 visualisation, we scaled some analyses so prescriptions on the first study month were the
170 reference, and report figures as a percentage change. As regional data (from ICBs) was available
171 for primary care data, we also ran analyses at the ICB level.

172

173 To compare with other classes/antibiotics, we performed a Z-test for the beta and standard
174 error of the linear regression for each class.²¹ For aid of visualisation, we also performed linear
175 regression of ratios (e.g. the ratio of co-amoxiclav to ciprofloxacin over calendar time).

176

177 Finally, for the time where it was available, we analysed data adjusted for inpatient population.
178 That is, we divided the number of prescriptions by the number of inpatients for each month to
179 generate prescriptions/month/patient.

180

181

182

183 *Software and codes*

184

185 We used R v 4.31 for analyses, and used the *tidyverse* package for data wrangling and plotting.²²
186 All code is available at <https://github.com/gushamilton/floroquinolone>, and the analysis is
187 completely replicable by running the same code locally. Regression was performed using the
188 linear regression model in R, while some plots fitted splines via ggplot.

189

190 *Ethics*

191

192 All data used in this analysis is publicly available. No ethics approval was therefore required.

193

194 *Funding*

195

196 FH's time was funded by the Wellcome Trust.

197

198 Results:

199


200 Our primary analysis focussed on primary care prescribing, where the risk-benefit ratio of
201 fluoroquinolone prescribing is most questioned. Across the study period (~5 years),
202 151,144,401 prescriptions for antibacterial agents were given across England, with an
203 estimated population of 59.6 million (2021 census data²³). This equates to 549 prescriptions per
204 year/1000 people. Approximately one fifth of this was made up of amoxicillin (125 prescriptions
205 per year per 1000 population). Fluoroquinolone represented a small proportion of antibiotics
206 prescribed (9 per year per 1000 population). This is visualised in **Figure 1A**.

207

208 Over the study period, antibacterial prescription was static (**Figure 1B**, +2% change per year;
209 95% CI -0.56% ; 4.6%, $p = 0.12$). However, fluoroquinolone prescription decreased substantially
210 over time (-4.2% 95% CI -5.2% ; -3.3%, $p = 6 \times 10^{-13}$, **Figure 1C**). This was driven by ciprofloxacin
211 reduction, which was 20 times more common than levofloxacin prescription. **Figure 1D** shows
212 these changes scaled so the first month was set to 1 for all products. This change in
213 fluoroquinolone prescribing was offset by a large increase in co-trimoxazole prescribing
214 (change per year +7.5% 95% CI (6.5% ; 8.5%), $p = 4.4 \times 10^{-22}$). No other tested antimicrobial
215 changed substantially. **Table 1** shows all estimates, with Z-tests comparing change in trends
216 versus all fluoroquinolones. This showed the trend in fluoroquinolone prescription was reduced
217 compared to all other antimicrobials.

218

219



220
 221 **Figure 1: Panel A** shows the items dispensed per year per 1000 population for a variety of
 222 antimicrobials and antimicrobial classes over the whole study period. **Panel B** shows the
 223 change over time in prescription of various antimicrobials: clarithromycin, co-amoxiclav, co-
 224 trimoxazole, and fluoroquinolones. All antibacterial usage over this time is plotted. **Panel C**
 225 shows just fluoroquinolones to help visualise the change, while, **panel D** shows the same as
 226 Panel B but rescaled so each drug class starts at 1. Linear regression lines shown with 95% CI.

227
 228
 229
 230
 231
 232
 233
 234
 235

236
237
238
239
240
241
242
243

Table 1: Estimates of the change in prescribing per year of each agent across the primary care study period.

Agent	% change per year (95% CI)	P value	P value for Z-test against trend for all fluoroquinolones*
Ciprofloxacin	-5.1% (-6% ; - 4.2%)	4.0e-16	8.9e-02
Fluoroquinolones	-4.2% (-5.2% ; - 3.3%)	6.2e-13	NA
Co-amoxiclav	-0.84% (-2.1% ; 0.37%)	1.7e-01	3.8e-06
Clarithromycin	-0.61% (-3.9% ; 2.7%)	7.1e-01	1.8e-02
Overall	2% (1.2% ; 2.7%)	3.7e-06	2.0e-25
Antibacterials	2% (-0.56% ; 4.6%)	1.2e-01	2.2e-06
Amoxicillin	2.5% (-2.4% ; 7.4%)	3.1e-01	3.5e-03
Penicillins	2.8% (-0.72% ; 6.2%)	1.2e-01	4.9e-05
Levofloxacin	3.8% (1.7% ; 5.8%)	5.7e-04	7.3e-13
Co-trimoxazole	7.5% (6.5% ; 8.5%)	4.4e-22	9.1e-69


244 *Z-test relative to fluoroquinolone coefficient, calculated as per.²¹ This compares whether there
245 is a difference between these two estimates (i.e. a difference in trend between the two agents).

246
247
248

249 There are 101 Integrated Care Boards (ICBs) in England. Over this period, only five care boards
250 reported an increase in fluoroquinolone usage, with only one (West Leicestershire, +3.1% 95%
251 CI, 1.5% ; 4.7%, 2.8×10^{-4} being measured with any statistical confidence (**Figure 2,**
252 **Supplementary Table 1**). In contrast, the majority of ICBs had large reductions in

253 fluoroquinolone usage, with 37% of ICBs reducing their prescription by 5% or more per year. The
254 biggest reduction came from NHS Oldham ICB, with a reduction in fluoroquinolone usage by -
255 12% per year 95% CI (-65% ; -47%, $p = 1 \times 10^{-23}$).

256
257
258
259




260

261 **Figure 2: Panel A** shows changes in prescribing of fluoroquinolones across ICBs. Multiple
262 linear regression lines across all 101 ICBs are fitted. Each line represents an ICB, with the faded
263 dots representing prescribing at that given month. **Panel B** shows the change per year for each
264 ICB plotted as a histogram. The black line represents no change per year, while the dotted red
265 line represents the overall change per year in England.

266
267
268 We then analysed data in secondary care. This is slightly more challenging as the weight of each
269 product in grams is provided, and then this was converted (assumptions in **Methods**) to
270 estimate and compare with the primary care data. In **Figure 3**, we compared estimates for
271 multiple antimicrobial classes in primary and secondary care. Fluoroquinolone usage was
272 generally higher in secondary care (around 50% higher total prescriptions), in contrast to
273 amoxicillin and clarithromycin, which were much more common in primary care. Co-
274 trimoxazole usage was much higher in secondary care. There was much more variability in
275 secondary care prescribing, particularly in early 2020, likely related to variability in hospital
276 occupancy rates the and cancellation of much elective surgery during the COVID-19
277 pandemic. Unlike in primary care, there were no clear trends identified for ciprofloxacin,
278 clarithromycin, or amoxicillin prescriptions over time in secondary care. However, there was
279 increasing usage of co-amoxiclav, co-trimoxazole, ceftriaxone, levofloxacin, and piperacillin-
280 tazobactam, over this period (all $p < 0.001$, **Table 2**).

281
282 Performing a Z-test comparing the regression coefficients, we identified evidence that all these
283 agents had increased prescribing relative to ciprofloxacin prescribing (Z-score p values in **Table**
284 **2**). This data suggests that although ciprofloxacin usage has been stable in secondary care
285 (+0.11% 95% CI, -1.7% ; 1.9%), the usage of comparable agents with similar spectra of activity
286 has increased relative to ciprofloxacin. Levofloxacin usage did increase over this time period
287 (+6.2% 95% CI, 3% ; 9.3%, $p = 2 \times 10^{-4}$, but again, relatively less co-trimoxazole and piperacillin-
288 tazobactam (both $p < 0.001$), and with a similar increase to ceftriaxone.

289
290



291

292 **Figure 3:** Prescribing (items/month) of various antimicrobial agents in primary and secondary
 293 care. Data taken from different sources and transformations applied, so interpret raw
 294 comparisons with caution. Linear regression with 95% confidence intervals fitted.

295

296 **Table 2:** Relative rates of prescribing of various antimicrobial agents in secondary care. The
 297 second column provides the percentage change per year, while the last two columns compare
 298 whether the trend is different to the ciprofloxacin or levofloxacin trend.

299

300

301

302

Agent	% change per year, (95% CI)	p-value	p-value for Z-test against Ciprofloxacin	p-value for Z-test against Levofloxacin
Co-trimoxazole	11% (9.9% ; 13%)	4.3e-21	1.1e-22	1.4e-03
Tazobactam	6.7% (5% ; 8.4%)	1.3e-10	3.3e-08	3.9e-01
Levofloxacin	6.2% (3% ; 9.3%)	2.3e-04	3.6e-04	5.0e-01
Ceftriaxone	5.1% (2.9% ; 7.3%)	1.9e-05	1.8e-04	2.9e-01
Amoxicillin	3.7% (1.4% ; 6%)	2.5e-03	7.1e-03	1.0e-01
Co-amoxiclav	3.3% (1.4% ; 5.2%)	8.1e-04	6.3e-03	5.7e-02
Ciprofloxacin	0.11% (-1.7% ; 1.9%)	9.0e-01	5.0e-01	3.6e-04
Meropenem	-0.65% (-2% ; 0.72%)	3.5e-01	2.5e-01	3.2e-05
Clarithromycin	-3.2% (-6.3% ; - 0.11%)	4.3e-02	3.1e-02	9.8e-06

303

304 *Z-test relative to ciprofloxacin coefficient, calculated as per.²¹ This compares whether there is
305 a difference between these two estimates (i.e. a difference in trend between the two agents).


306

307 To aid comparison, a final plot showing the ratio of prescribing relative to ciprofloxacin is shown
308 in **Figure 4**. This shows that over the study period, the relative prescribing of ciprofloxacin has
309 fallen. At the start of 2020, approximately 3 prescriptions containing amoxicillin were given for
310 each ciprofloxacin prescription, by late 2023, this was nearly 4. This trend is shown for all tested
311 agents except meropenem, clarithromycin, and levofloxacin, which has a relative increase
312 compared to ciprofloxacin (although small on the absolute terms, of 0.36% per year).

313

314

315



316

317

318

319

320

321

322

323

324

325

326

327

328


329

330

Figure 4: The relative ratio of prescription of each of the above antibacterial agents in secondary care, as compared to ciprofloxacin, over time. Linear regression fitted with 95% confidence intervals.

Finally, from December 2020, we had access to monthly bed occupancy from NHS England and used this to adjust and generate estimated prescriptions per admitted person per month. This period starts >1 year after the MHRA and EMA warnings, and inspection of Figure 3 shows an already steep drop in ciprofloxacin prescribing between 2020 and 2021 of around 15%, which would not be captured in this analysis. Between December 2020 and December 2023, there was a large rise in occupied beds, from around 78,000 to 92,000 inpatients (~15% increase, **Supplementary Figure 1**). When adjusting for hospital bed utilisation, we identified a reduction in ciprofloxacin (but not levofloxacin usage), with -2% reduction in prescribing per year 95% CI (-3.9% ; -0.15%, $p = 0.04$, **Figure 5**). Given the steep drop prior to this time period this analysis

331 shows that relative to hospital utilisation, reductions in secondary care prescribing are similar,
332 although slight smaller, than in primary care for ciprofloxacin. In contrast, levofloxacin
333 prescription did increase (+4.5% 95% CI +0.63% ; +8.3%), meaning overall fluoroquinolone
334 prescriptions were stable (-0.8%; 95% CI -2.5%; +0.8%).
335



336
337 **Figure 5:** Prescriptions of each agent, adjusted for hospital utilisation, so the Y-axis is on the
338 scale of prescriptions per inpatient per month. Linear regression (blue line) fitted with 95% CI
339 (grey area)

340
341
342

343 Discussion:

344

345 Our work uses both primary and secondary care data for the whole of England to explore
346 fluoroquinolone prescriptions over the last five years and assess the influence of EMA/MHRA
347 restrictions on prescribing. We identified clear reductions in primary care prescribing of
348 ciprofloxacin, which accounted for the vast majority of all primary care fluoroquinolone
349 prescriptions. This was in contrast to usage of comparator antibiotics that were largely static.

350

351 In secondary care, antimicrobial prescribing varied much more, likely due to the COVID-19
352 pandemic. Absolute ciprofloxacin prescribing was stable across the time period. However,
353 comparator antibiotic prescriptions increased, consistent with a relative reduction in
354 ciprofloxacin prescribing. For the time period from December 2020 onwards (by which time a
355 ~15% reduction in ciprofloxacin prescribing had occurred), we had hospital utilisation data.
356 When adjusting for this, relative ciprofloxacin usage reduced by around 2% per year. This is
357 consistent with increased pressure and workload on the NHS in England, while maintaining
358 relatively infrequent use of fluoroquinolones compared to other agents ?. Levofloxacin
359 prescription did, however, increase.

360

361 One major reason for the continued use of fluoroquinolones in secondary care is that there are
362 remarkably few good oral options for the therapy of some infections. Potential agents often
363 require intravenous administration, and there is also pressure to reduce the use of certain other
364 agents (e.g. third generation cephalosporins, Beta-lactam-beta-lactamase inhibitors and
365 carbapenems). Resistance rates to co-trimoxazole and co-amoxiclav in Gram negatives are
366 ~30%, with ciprofloxacin at only 17% in the recent ESPAUR report.²⁴ Additionally, some
367 randomised trial data and meta-analyses, particularly in pneumonia, suggests that
368 fluoroquinolones are superior to other options in this condition, which is the main reason for
369 antimicrobial prescribing in acute admissions.²⁵ Other indications for fluoroquinolones may be
370 relatively uncommon in terms of proportional numbers of patients affected , but by their nature
371 require prolonged courses for up to 3-6 months , for example prosthetic joint or vascular
372 implant infection.

373

374 As far as we are aware, the only other study examining post EMA/MHRA fluoroquinolone
375 prescribing trends is Ly et al, funded by the EMA and analysing UK data from 2016-2020¹⁵. This
376 study used a multisegmented regression approach to identify monthly percentage changes in
377 relation to specific communications from regulators. Although this study is reported in the
378 MHRA Drug Safety Update as showing 'no change' in prescribing, it does show a reduction in
379 fluoroquinolone prescribing, and is estimated by Ly et al to be "at best, a reduction in
380 prescriptions of around 25%".¹⁵ As such, our results are concordant and extend the study period
381 and show further reductions since then. The English Surveillance Programme for Antimicrobial
382 Utilisation and Resistance (ESPAUR) report for 2023 provides supportive data, with quinolone
383 prescription dropping from 0.565 in 2018 to 0.456 in 2022 (p = 0.04).²⁴ Interestingly, a study of all
384 antimicrobial prescribing over a longer period (2014-2024), identified a reduction in overall
385 antibiotic prescribing, whereas our data suggested largely static antimicrobial prescribing.²⁶

386

387 Limitations of our study include its entirely ecological focus. We had no access to individual
388 level data, and so we can only focus on trends without deeper insight. Interpretation of our
389 secondary care data was reliant on transformation of product weight into assumed product
390 courses, although these transformations would only change absolute differences between
391 comparator antibiotics, and not changes in trend. Our use of hospitalisation data as a proxy for
392 hospital pressure is imperfect, and only reflects total inpatients (not, e.g. admissions). Given
393 fluoroquinolones are used in both acute admissions and inpatients, it would be challenging to
394 accurately model hospital pressure, and inpatient hospitalisation is a reasonable proxy.

395

396

397 In summary, national prescribing data for England shows an approximate 5% reduction per year
398 in ciprofloxacin prescribing in primary care, where there is the most concern about
399 ‘inappropriate’ prescribing of this drug class. This is clearly a large, statistically precise, and
400 important reduction, which has continued over the 5-year period however the exact reasons for
401 this reduction cannot be determined from this data.

402

403

404

405 Funding

406

407 FH's time was funded by the Wellcome Trust (222894/Z/21/Z)

408

409 Competing interests:

410

411 No author declares any competing interests.

412

413

414

415 References:

416

417

418 1. Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev [Internet]
419 1989;2(4):378–424. Available from: <http://dx.doi.org/10.1128/CMR.2.4.378>

420 2. Fluoroquinolone antibiotics: must now only be prescribed when other commonly
421 recommended antibiotics are inappropriate [Internet]. Gov.uk. 2024 [cited 2024 Feb
422 3]; Available from: [https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-](https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-must-now-only-be-prescribed-when-other-commonly-recommended-antibiotics-are-inappropriate)
423 [must-now-only-be-prescribed-when-other-commonly-recommended-antibiotics-are-](https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-must-now-only-be-prescribed-when-other-commonly-recommended-antibiotics-are-inappropriate)
424 [inappropriate](https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-must-now-only-be-prescribed-when-other-commonly-recommended-antibiotics-are-inappropriate)

425 3. Overview | Pneumonia in adults: diagnosis and management | Guidance | NICE. [cited 2024
426 Feb 3]; Available from: <https://www.nice.org.uk/guidance/cg191>

427 4. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-
428 acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic
429 Society and Infectious Diseases Society of America. Am J Respir Crit Care Med [Internet]
430 2019;200(7):e45–67. Available from: <http://dx.doi.org/10.1164/rccm.201908-1581ST>

431 5. Fifer H, Saunders J, Soni S, Sadiq ST, FitzGerald M. 2018 UK national guideline for the
432 management of infection with Neisseria gonorrhoeae. Int J STD AIDS [Internet]
433 2020;31(1):4–15. Available from: <http://dx.doi.org/10.1177/0956462419886775>

434 6. Nabarro LE, McCann N, Herdman MT, et al. British infection association guidelines for the
435 diagnosis and management of enteric fever in England. J Infect [Internet] 2022;84(4):469–
436 89. Available from: <http://dx.doi.org/10.1016/j.jinf.2022.01.014>

437 7. Overview | Pyelonephritis (acute): antimicrobial prescribing | Guidance | NICE. [cited 2024
438 Feb 3]; Available from: <https://www.nice.org.uk/guidance/ng111>

439 8. WHO consolidated guidelines on tuberculosis [Internet]. World Health Organization; 2022
440 [cited 2024 Feb 3]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK588564/>

441 9. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases
442 Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-
443 Negative Infections. Clin Infect Dis [Internet] 2023; Available from:
444 <http://dx.doi.org/10.1093/cid/ciad428>

- 445 10. Baggio D, Ananda-Rajah MR. Fluoroquinolone antibiotics and adverse events. *Aust Prescr*
446 [Internet] 2021;44(5):161–4. Available from:
447 <http://dx.doi.org/10.18773/austprescr.2021.035>
- 448 11. Center for Drug Evaluation, Research. FDA reinforces safety information about serious low
449 blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires
450 label changes [Internet]. U.S. Food and Drug Administration. 2019 [cited 2024 Feb
451 3]; Available from: [https://www.fda.gov/drugs/drug-safety-and-availability/fda-reinforces-](https://www.fda.gov/drugs/drug-safety-and-availability/fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side)
452 [safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side](https://www.fda.gov/drugs/drug-safety-and-availability/fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side)
- 453 12. Quinolone- and fluoroquinolone-containing medicinal products - referral [Internet]. [cited
454 2024 Feb 2]; Available from:
455 [https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-and-](https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-and-fluoroquinolone-containing-medicinal-products)
456 [fluoroquinolone-containing-medicinal-products](https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-and-fluoroquinolone-containing-medicinal-products)
- 457 13. Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare
458 reports of disabling and potentially long-lasting or irreversible side effects [Internet].
459 Gov.uk. 2019 [cited 2024 Feb 3]; Available from: [https://www.gov.uk/drug-safety-](https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects)
460 [update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-](https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects)
461 [very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects](https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects)
- 462 14. Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or
463 irreversible side effects [Internet]. Gov.uk. 2023 [cited 2024 Feb 2]; Available from:
464 [https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-reminder-of-the-risk-](https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-reminder-of-the-risk-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects)
465 [of-disabling-and-potentially-long-lasting-or-irreversible-side-effects](https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-reminder-of-the-risk-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects)
- 466 15. Ly NF, Flach C, Lysen TS, et al. Impact of European Union Label Changes for
467 Fluoroquinolone-Containing Medicinal Products for Systemic and Inhalation Use: Post-
468 Referral Prescribing Trends. *Drug Saf* [Internet] 2023;46(4):405–16. Available from:
469 <http://dx.doi.org/10.1007/s40264-023-01286-4>
- 470 16. Bennett Institute for Applied Data Science, University of Oxford. OpenPrescribing
471 [Internet]. , 2024 [cited 2024 Feb 2]; Available from: <https://openprescribing.net/>
- 472 17. Sanderson T. A web tool for the exploration of hospital prescription data in England
473 [Internet]. medRxiv. 2023 [cited 2024 Feb 2]; 2023.12.14.23299817. Available from:
474 <https://www.medrxiv.org/content/10.1101/2023.12.14.23299817v1.abstract>
- 475 18. NHS Business Authority. NHS SCMD. Available from:
476 <https://opendata.nhsbsa.net/dataset/secondary-care-medicines-data-indicative-price>
- 477 19. Statistics. Critical Care and General Acute Beds (NHS England) [Internet]. [cited 2024 Feb
478 3]; Available from: [https://www.england.nhs.uk/statistics/statistical-work-areas/hospital-](https://www.england.nhs.uk/statistics/statistical-work-areas/hospital-activity/monthly-hospital-activity/mar-data/)
479 [activity/monthly-hospital-activity/mar-data/](https://www.england.nhs.uk/statistics/statistical-work-areas/hospital-activity/monthly-hospital-activity/mar-data/)
- 480 20. Turner SL, Karahalios A, Forbes AB, Taljaard M, Grimshaw JM, McKenzie JE. Comparison of
481 six statistical methods for interrupted time series studies: empirical evaluation of 190


- 482 published series. BMC Med Res Methodol [Internet] 2021;21(1):134. Available from:
483 <http://dx.doi.org/10.1186/s12874-021-01306-w>
- 484 21. Clogg CC, Petkova E, Haritou A. Statistical Methods for Comparing Regression Coefficients
485 Between Models. Am J Sociol [Internet] 1995;100(5):1261–93. Available from:
486 <https://doi.org/10.1086/230638>
- 487 22. Wickham H, Averick M, Bryan J, et al. Welcome to the tidyverse. J Open Source Softw
488 [Internet] 2019;4(43):1686. Available from:
489 <https://joss.theoj.org/papers/10.21105/joss.01686>
- 490 23. Roskams M. Population and household estimates, England and Wales - Office for National
491 Statistics [Internet]. 2022 [cited 2024 Feb 10];Available from:
492 [https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/popula
493 tionestimates/bulletins/populationandhouseholdestimatesenglandandwales/census2021
494 unroundeddata](https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationandhouseholdestimates/bulletins/populationandhouseholdestimatesenglandandwales/census2021unroundeddata)
- 495 24. UKHSA. English surveillance programme for antimicrobial utilisation and resistance
496 (ESPAUR). 2023;Available from:
497 [https://assets.publishing.service.gov.uk/media/6555026e544aea000dfb2e19/ESPAUR-
498 report-2022-to-2023.pdf](https://assets.publishing.service.gov.uk/media/6555026e544aea000dfb2e19/ESPAUR-report-2022-to-2023.pdf)
- 499 25. Choi S-H, Cesar A, Snow TAC, Saleem N, Arulkumaran N, Singer M. Respiratory
500 fluoroquinolone monotherapy vs. β -lactam plus macrolide combination therapy for
501 hospitalized adults with community-acquired pneumonia: A systematic review and meta-
502 analysis of randomized controlled trials. Int J Antimicrob Agents [Internet]
503 2023;62(3):106905. Available from: <http://dx.doi.org/10.1016/j.ijantimicag.2023.106905>
- 504 26. McCloskey AP, Malabar L, McCabe PG, Gitsham A, Jarman I. Antibiotic prescribing trends in
505 primary care 2014-2022. Res Social Adm Pharm [Internet] 2023;19(8):1193–201. Available
506 from: <http://dx.doi.org/10.1016/j.sapharm.2023.05.001>

507

508

509 Supplementary Figures:

510



511
512 **Figure S1:** Bed utilisation in English NHS trusts from December 2020 until December 2023.
513 Data from NHS England.

514
515
516

